Specific features of hypercalcaemia in patients of Cocody University Hospital - Côte d’Ivoire
##plugins.themes.academic_pro.article.main##
Abstract
Aim: describe the epidemiological, clinical, etiological and therapeutic aspects of hypercalcemia seen in the rheumatology department of Cocody University Hospital.
Patients and method: Descriptive cross-sectional study carried out in the rheumatology department of Cocody University Hospital from January 2013 to July 2022 and covering the files of patients with hypercalcemia.
Results: The hospital frequency of hypercalcemia was 0.88%, or 60 cases out of 6771 hospitalizations during the study period. The workforce included 35 men and 25 women (M/F ratio=0.14), aged on average 56±11.52 years (range 25 and 80 years). The main reason for consultation related to the underlying disease was osteoarticular pain syndrome. The signs related to symptomatic hypercalcemia were digestive (23.33%), neurological (8.33%) and cardiovascular (5%). The main extra-articular signs were asthenia (90%) and weight loss (78.33%). On the biological level, there was a clear predominance of mild hypercalcemia (76.67%), followed by moderate hypercalcemia (10%) and severe hypercalcemia (13.33%). The etiologies were dominated by multiple myeloma (45%), followed by bone metastases (40%), granulomatosis (13.33%) and secondary hyperparathyroidism (1.67%). The molecules used for the treatment of hypercalcemia were corticosteroids and biophosphonates. The outcome was favorable in 18.33% of patients, and unspecified in 66.67% of cases due to the patient's transfer to another department. There were 9 deaths, or 15% of cases.
Conclusion: Hypercalcemia is rare and most often asymptomatic in rheumatological hospitalizations in Abidjan. Multiple myeloma is the main etiology.
Keywords:
hypercalcemia , multiple myeloma , osteophilic cancer , Africa , Ivory Coast##plugins.themes.academic_pro.article.details##
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
- - Andronikof M. Dyscalcémies. Médecine d’urgence. EMC. Paris : Elsevier Masson SAS. 2010 ,25-100-A-23.
- - Guitton C, Renard B, Gabillet L, Villers D. Dyscalcémie aux urgences. Réanimation : Éditions scientifiques et médicales Elsevier SAS ; 2002, 11 : 493-501.
- - Mansouri S, Abourazzak ZF, Harzy T. Diagnostic d’une hypercalcémie. Rev Mar Rhum 2012;19:28-33.
- - Kodio B, Pamanta IS, Touré S, Touré M, Traoré M, Cissé IA. Profils épidémioclinique et étiologique des hypercalcémies vues dans le Service de Rhumatologie au CHU du Point G (Mali). Revue du Rhumatisme 83S (2016) A163-A304
- - Vieillard MH, Gerot-Legroux I. Hypercalcémie de l’adulte. EMC. Paris : Elsevier Masson SAS-appareil locomoteur ; 2009 :14-002-E-10.
- - Boujelben K, Garbouj W, Amri R, Tounsi H, Fraj A, Chabene I. Profil clinique et étiologique des hypercalcémies chez le sujet âgé dans un service de médecine interne : à propos de 12 cas. Annales d’Endocrinologie 79 (2018) 414 - 434
- - Manier S, Leleu X. Myélome multiple : diagnostic clinique et perspective de traitement. Recommandations de l’International Myeloma Working Group (IMWG). Immuno-analyse et biologie spécialisée (2011) 26, 125-136
- - Mongiat-Artus P, Brenot-Ross I, Beuzeboc P et al. Le traitement non hormonal de la maladie métastatique du cancer de la prostate. Progrès en urologie (2013) 23, 1258-1264
- - Dosumu EA, Momoh JA. Hypercalcemia in patients with newly diagnosed tuberculosis in Abuja, Nigeria. Can Respir J Vol 13 No 2 March 2006
- - Hamdi W, Néji O, Ghannouchi MO, Kaffel D, Kchir MM. Les manifestations rhumatologiques de la sarcoïdose. La Tunisie Medicale - 2010 ; Vol 88 (n°11) :773-782
- - Francoise Debiais. Diagnostic des hypercalcémies « non hyperparathyroïdiennes ». Revue du rhumatisme monographies 79 (2012), 227–232
- - Guay DR. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy. Pharmacotherapy 2006;26:655-73.
- - Henrich D, Hoffmann M, Uppenkamp M, Bergner R. Ibandronate for the treatment of hypercalcemia or nephrocalcinosis in patients with multiple myeloma and acute renal failure: case reports. Acta Haematol 2006; 116:165-72.
- - De Cock E, Hutton J, Canney P, Body JJ, Barrett-Lee P, Neary PM, Lewis G. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. Clin Ther 2005;27:1295-310.
- - Machado M, Cruz LS, Tannus G, Fonseca M. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials. Clin Ther 2009; 31:962-79.
- - Kaminski M, Rosen L, Gordon D, Zheng M, Hei YJ. Zoledronic acid is superior to pamidronate in patients with breast cancer and multiple myeloma who are at high risk for skeletal complications. The Breast 2005; 14:S45.